...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Secondary to Interaction Between Methotrexate and Etoricoxib: A Case Report
【24h】

Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Secondary to Interaction Between Methotrexate and Etoricoxib: A Case Report

机译：史蒂文斯·约翰逊综合症继甲氨蝶呤和依托考昔之间相互作用后的毒性表皮坏死交叠：一例

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis (RA) is an autoimmune disease affecting about 1% of people, with the highest incidence between 40 and 70 years. Methotrexate is an anti-folate analogue that has good efficacy and safety in the treatment of RA. Methotrexate (MTX) and non-steroidal anti inflammatory drugs are often concomitantly administered in clinical practice for the treatment of RA. In this case report, a 57-year-old female was treated with oral methotrexate 7.5 mg per week for a diagnosed case of RA. Since her pain persisted after completing six weeks of treatment with methotrexate, oral etoricoxib 60 mg once daily was added to the treatment regimen. Six weeks later, the patient complained of oral ulcerations and blisters on all fours limbs and trunk. The patient was re-evaluated and was diagnosed with Stevens-Johnson syndrome-Toxic epidermal necrolysis (SJS-TEN) overlap. This case highlights the possible pharmacokinetic interaction between methotrexate and etoricoxib that has a significant clinical implication.
机译：类风湿关节炎（RA）是一种自身免疫性疾病，约有1％的人受到感染，发病率最高的时期为40至70岁。甲氨蝶呤是一种抗叶酸类似物，在RA的治疗中具有良好的疗效和安全性。甲氨蝶呤（MTX）和非甾体类抗炎药通常在临床实践中同时用于RA的治疗。在此病例报告中，一名57岁的女性接受了每周7.5 mg甲氨蝶呤口服治疗，诊断为RA。由于用甲氨蝶呤治疗6周后她的疼痛仍然存在，因此每天60 mg的口服依托考昔单次口服治疗。六周后，患者主诉四肢和躯干出现口腔溃疡和水泡。对该患者进行了重新评估，并被诊断出史蒂文斯-约翰逊综合征与中毒性表皮坏死溶解（SJS-TEN）重叠。该病例强调了甲氨蝶呤和依托考昔之间可能存在的药代动力学相互作用，具有重要的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号